Squibb-Novo new pre-mixed insulin
Executive Summary
Novolin 70/30, the first product in the U.S. combining 70% intermediate-acting and 30% regular short-acting human insulin ratio in one vial, has been approved for distribution. Squibb-Novo said the ratio is the most frequently prescribed for patients who mix insulin.